COCHLEAR LIMITED (COH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.41
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$320.06

12 Apr
2024

-0.940

OPEN

$319.81

-0.29%

HIGH

$321.49

72,809

LOW

$318.22

TARGET
$257.75 -19.5% downside
Franking for last dividend paid out: 70%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
COH: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 601.5 xxx
DPS (cps) xxx N/A 419.6 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 53.2 xxx
Dividend Yield xxx N/A 1.3% xxx
Div Pay Ratio(%) xxx N/A 69.8% xxx

Dividend yield today if purchased 3 years ago: 1.47%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.03

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 21/03 - ex-div 200c (franking 70%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx457.1
DPS All xxxxxxxxxxxxxxx330.0
Sales/Revenue xxxxxxxxxxxxxxx1,955.7 M
Book Value Per Share xxxxxxxxxxxxxxx2,662.9
Net Operating Cash Flow xxxxxxxxxxxxxxx362.4 M
Net Profit Margin xxxxxxxxxxxxxxx15.37 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx17.50 %
Return on Invested Capital xxxxxxxxxxxxxxx15.94 %
Return on Assets xxxxxxxxxxxxxxx11.94 %
Return on Equity xxxxxxxxxxxxxxx17.50 %
Return on Total Capital xxxxxxxxxxxxxxx21.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx115.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx39 M
Long Term Debt xxxxxxxxxxxxxxx163 M
Total Debt xxxxxxxxxxxxxxx202 M
Goodwill - Gross xxxxxxxxxxxxxxx256 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx556 M
Price To Book Value xxxxxxxxxxxxxxx8.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx95.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx488 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,055 M
Research & Development xxxxxxxxxxxxxxx245 M
Investments - Total xxxxxxxxxxxxxxx99 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.8

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

20/02/2024

5

Underperform

$255.00

-20.33%

Cochlear's December-half result missed Macquarie's forecasts despite revenue and net profit after tax being pre-reported due to an inventory writedown.

Operating expenditure proved a beat.

Management reiterated sales guidance (in line with Macquarie's forecasts).

EPS forecasts fall -1% in FY24; -1% in FY; and -3% in FY26.

Underperform rating retained, the broker believing the share price is outpacing projected sales. Target price eases to $255 from $260.00.

FORECAST
Macquarie forecasts a full year FY24 dividend of 425.00 cents and EPS of 610.00 cents.
Macquarie forecasts a full year FY25 dividend of 500.00 cents and EPS of 719.00 cents.

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

COH STOCK CHART